Sandbox Reserved 895: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 83: Line 83:
Emixustat (ACU-4429) shown in '''Figure 7''' is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. When synthesized, emixustat usually presents of a racemic mixture of (''R'')-emixustat and (''S'')-emixustat. The (''R'')-isomer is associated with increased binding affinity and potency and is used in drug development and research. Formulated as a hydrochloride salt, (''R'')-emixustat hydrochloride is taken by mouth and functions as a visual cycle modulator (VCM) in atrophic (dry) age related macular degeneration (AMD). (''R'')-emixustat has been shown to reduce toxic retinal byproducts in the retinoid cycle such as N-retinylidiene-N-retinylethanolamine (A2E).  
Emixustat (ACU-4429) shown in '''Figure 7''' is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. When synthesized, emixustat usually presents of a racemic mixture of (''R'')-emixustat and (''S'')-emixustat. The (''R'')-isomer is associated with increased binding affinity and potency and is used in drug development and research. Formulated as a hydrochloride salt, (''R'')-emixustat hydrochloride is taken by mouth and functions as a visual cycle modulator (VCM) in atrophic (dry) age related macular degeneration (AMD). (''R'')-emixustat has been shown to reduce toxic retinal byproducts in the retinoid cycle such as N-retinylidiene-N-retinylethanolamine (A2E).  


[[Image:Figrue7_Emixustat.jpg|thumb|center|512 px|alt=Figure 7: Emixustat| '''Figure 7:''' (''R'')-Emixustat]]
[[Image:Figure7_Emixustat.jpg|thumb|center|512 px|alt=Figure 7: Emixustat| '''Figure 7:''' (''R'')-Emixustat]]


In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the continued development of (''R'')-emixustat as a potential inhibitor of RPE65. Currently (''R'')-emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of dry AMD. Additionally, (''R'')-emixustat is investigated as a potential therapy for diabetic retinopathy and diabetic macular edema. <ref> Maekawa H. Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients With Stargardt Disease. BioSpace. 13 Feb 2020. Available from: https://www.biospace.com/article/releases/acucela-provides-update-on-emixustat-phase-3-clinical-trial-in-patients-with-stargardt-disease/ </ref>
In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the continued development of (''R'')-emixustat as a potential inhibitor of RPE65. Currently (''R'')-emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of dry AMD. Additionally, (''R'')-emixustat is investigated as a potential therapy for diabetic retinopathy and diabetic macular edema. <ref> Maekawa H. Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients With Stargardt Disease. BioSpace. 13 Feb 2020. Available from: https://www.biospace.com/article/releases/acucela-provides-update-on-emixustat-phase-3-clinical-trial-in-patients-with-stargardt-disease/ </ref>
Line 99: Line 99:
The difference in bond lengths also confirms the increase in binding affinity and potency of the (R)-isomer. These interactions can be seen in '''Figure 9''' . <ref> DOI 26075817 </ref>
The difference in bond lengths also confirms the increase in binding affinity and potency of the (R)-isomer. These interactions can be seen in '''Figure 9''' . <ref> DOI 26075817 </ref>


[[Image:Figrue9_R_S_Emixustat_binding_pocket.jpg|thumb|center|512 px|alt=Figure 9ABCD: R and S Emixustat Binding Pocket| '''Figure 9:''' (A) Circular Dichroism on R, the (''R'')-isomer; M, the Racemic mixutre; and S, the (''S'')-isomer (B) Racemic emixustat bound to the RPE65 binding pocket (C) (''R'')-emixustat bound to the RPE65 binding pocket (D) (''S'')-emixustat bound to the RPE65 binding pocket <ref> DOI 26075817 </ref>]]
[[Image:Figure9_R_S_Emixustat_binding_pocket.jpg|thumb|center|512 px|alt=Figure 9ABCD: R and S Emixustat Binding Pocket| '''Figure 9:''' (A) Circular Dichroism on R, the (''R'')-isomer; M, the Racemic mixutre; and S, the (''S'')-isomer (B) Racemic emixustat bound to the RPE65 binding pocket (C) (''R'')-emixustat bound to the RPE65 binding pocket (D) (''S'')-emixustat bound to the RPE65 binding pocket <ref> DOI 26075817 </ref>]]




Retrieved from "https://proteopedia.org/Sandbox_Reserved_895"